Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

NCT01297764 is registered in ClinicalTrials.gov with Hackensack Meridian Health as lead sponsor.

NCT NCT01297764
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01297764 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
Lead sponsor
Hackensack Meridian Health
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
April 30, 2011
Completion date
June 30, 2027
Enrollment
17 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma